ArticleArchives of toxicology2020
Surface carboxylation or PEGylation decreases CuO nanoparticles' cytotoxicity to human cells in vitro without compromising their antibacterial properties.
Article in Archives of toxicology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Cell-free DNA in sepsis: from molecular insights to clinical management.Military Medical Research · 2025Review
- Metal nanoparticles in cancer theranostics: from synthesis to tumor microenvironment-responsive applications.Drug delivery · 2025Review
- Impact of a Novel Pretreatment on Bond Strength of Universal Adhesive to Conventional and CAD/CAM Resin Composites: In Vitro Study.Journal of functional biomaterials · 2025Article
- Let the two sides of the same coin meet-Environmental health and safety-oriented development of functional nanomaterials for environmental remediations.Eco-Environment & Health · 2024Review
- Synergistic antibacterial effect of copper and silver nanoparticles and their mechanism of action.Scientific reports · 2023Article
- Antibacterial and Antiviral Effects of Ag, Cu and Zn Metals, Respective Nanoparticles and Filter Materials Thereof against Coronavirus SARS-CoV-2 and Influenza A Virus.Pharmaceutics · 2022Article
- Antibacterial Bio-Nanocomposite Textile Material Produced from Natural Resources.Nanomaterials (Basel, Switzerland) · 2022Article
- An Integrated Testing Strategy for Ecotoxicity (ITS-ECO) Assessment in the Marine Environmental Compartment using Mytilus spp.: A Case Study using Pristine and Coated CuO and TiOEnvironmental toxicology and chemistry · 2022Article
- Copper oxide nanoparticles trigger macrophage cell death with misfolding of Cu/Zn superoxide dismutase 1 (SOD1).Particle and fibre toxicology · 2022Article
- Copper-containing nanoparticles: Mechanism of antimicrobial effect and application in dentistry-a narrative review.Frontiers in surgery · 2022Review
- Copper Oxide Nanoparticles Stimulate the Immune Response and Decrease Antioxidant Defense in Mice After Six-Week Inhalation.Frontiers in immunology · 2022Article
- Recent Discoveries in Nanoparticle-Macrophage Interactions: In Vitro Models for Nanosafety Testing and Novel Nanomedical Approaches for Immunotherapy.Nanomaterials (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical use of CuO nanoparticles (NPs) as antibacterials can be hampered by their toxicity to human cells. We hypothesized that certain surface functionalizations of CuO NPs may render NPs toxic to bacteria, but still be relatively harmless to human cells. To control this hypothesis, the toxicity of differently functionalized CuO NPs to bacteria Escherichia coli vs human cells (THP-1 macrophages and HACAT keratinocytes) was compared using similar conditions and end points. CuO NPs functionalized with polyethylene glycol (CuO-PEG), carboxyl (CuO-COOH, anionic), ammonium (CuO-NH
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.